Jefferies Positive On Dynavax (DVAX) and Heplisav

Jefferies reiterated their Buy and $4 price target on Dynavax Technologies Inc. (NASDAQ: DVAX) following a presentation at the Jefferies 2011 Global Healthcare Conference.

The firm states, "We continue to believe Heplisav may become the preferred HBV vaccine for poor responders to current vaccines and to see diabetes as a major new opportunity not captured in the current valuation. We expect Heplisav approval in late 2012/early 2013, with a potential vote on the diabetes mandate as early as October. At our healthcare conference, DVAX management provided several positive clinical and regulatory updates on Heplisav."

For more ratings news on Dynavax Technologies click here and for the rating history of Dynavax Technologies click here.

Shares of Dynavax Technologies closed at $2.51 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'
• Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results